PTC Therapeutics
PTCT
382 hedge funds and large institutions have $8.2B invested in PTC Therapeutics in 2026 Q2 according to their latest regulatory filings, with 76 funds opening new positions, 143 increasing their positions, 112 reducing their positions, and 44 closing their positions.
583% more call options, than puts
Call options by funds: $72.2M | Put options by funds: $10.6M
73% more first-time investments, than exits
New positions opened: 76 | Existing positions closed: 44
28% more repeat investments, than reductions
Existing positions increased: 143 | Existing positions reduced: 112
26% more capital invested
Capital invested by funds: $6.51B → $8.2B (+$1.69B)
9% more funds holding
Funds holding: 352 → 382 (+30)
5.05% more ownership
Funds ownership: 115.41% → 120.46% (+5.1%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
+$141M |
| 2 |
William Blair Investment Management
Chicago,
Illinois
|
+$124M |
| 3 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$83.5M |
| 4 |
BlackRock
New York
|
+$73.4M |
| 5 |
BSL
Blue Sparrow LLC
Dover,
Delaware
|
+$62.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$79.6M |
| 2 |
AC
Armistice Capital
New York
|
-$72.4M |
| 3 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$62.1M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$50.8M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$39.1M |
PTCT Hedge Fund Activity: Q2 2026 in Review
382 of the 8,349 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q2 2026, worth a combined $8.2B — up 26% from $6.51B a quarter earlier.
Buyers outnumbered sellers: 76 funds opened new PTCT positions and 44 closed out — a net gain of 32 holders — while 143 added to existing stakes and 112 trimmed.
The largest buyer was Westfield Capital Management, opening a new position worth an estimated $141M. The largest seller was UBS Group, cutting an estimated $79.6M.
- 382 institutional investors held PTC Therapeutics (PTCT) as of Q2 2026, up from 352 in Q1 2026.
- Funds reported $8.2B of PTC Therapeutics stock for Q2 2026, up 26% quarter-over-quarter.
- 76 funds opened new PTC Therapeutics positions in Q2 2026 and 44 closed out, a net change of +32 holders.
- The largest PTC Therapeutics buyer in Q2 2026 was Westfield Capital Management, an estimated $141M added.
- The largest PTC Therapeutics seller in Q2 2026 was UBS Group, an estimated $79.6M sold.
Based on aggregated 13F filings for Q2 2026.